GLP-1 Receptor Agonists in Orthopedic Surgery: Friend or Foe?

Montero A Kearney A Mulugeta M Kirzinger A Hamel L . KFF health tracking poll: prescription drug costs, view on Trump Administration actions, and GLP-1 use. KFF. Updated November 14, 2025. Accessed April 21, 2026. https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/

Mavrogenis AF Altsitzioglou P Pililis S , et al. Glucagon-like peptide-1 receptor agonists in orthopaedics. SICOT J. 2026;12:E1. https://doi.org/10.1051/sicotj/2025067

Kindel TL Wang AY Wadhwa A , et al; American Gastroenterological Association; American Society for Metabolic and Bariatric Surgery; American Society of Anesthesiologists; International Society of Perioperative Care of Patients with Obesity; Society of American Gastrointestinal and Endoscopic Surgeons. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Clin Gastroenterol Hepatol. 2025;23(12):2083-2085. https://doi.org/10.1016/j.cgh.2024.10.003

Wajahath M Lawand JJ Hill BW Khan A Abboud JA Horneff JG. GLP1 receptor agonist use is associated with increased risk of osteoporosis, gout, and osteomalacia in adults with type 2 diabetes and obesity [conference abstract]. Presented at: American Academy of Orthopaedic Surgeons Annual Meeting; March 2-6, 2026; New Orleans, LA. Accessed April 21, 2026. https://submissions.mirasmart.com/Verify/AAOS2026/Submission/out/AAOS2026-008736.PDF